Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03610711 · ClinicalTrials.gov registry record · Phase 1
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
A Phase 1 study of GastroEsophageal Cancer and Immune Checkpoint Inhibition, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Active
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 3
- Study locations
NCT03610711: Active Phase 1 study of GastroEsophageal Cancer and Immune Checkpoint Inhibition, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT03610711 is a Phase 1 study of GastroEsophageal Cancer and Immune Checkpoint Inhibition that is active but no longer recruiting, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 21 participants, below the 496-participant average among 23 other GastroEsophageal Cancer trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03610711, a Phase 1 study of GastroEsophageal Cancer and Immune Checkpoint Inhibition, is active but no longer recruiting, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a Phase 1B study assessing the safety of immune checkpoint inhibition after SBRT in patients with recurrent or metastatic gastroesophageal cancer (limited metastatic disease).
Primary Outcome
Change in the infiltrating CD8+ T cell density units pre- and post-systemic treatment with radiation plus nivolumab +/- Relatlimib in the non-irradiated metastatic lesion.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Relatlimab
Study Locations (3)
Maryland
- Johns Hopkins University - Baltimore
Pennsylvania
- Alleghany Health Network - Pittsburgh
Texas
- Baylor University - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2019-03-06 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What the registry record for NCT03610711 still lists
NCT03610711 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 496-participant average among 23 other GastroEsophageal Cancer trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with GastroEsophageal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT03610711 reports a single indexed study location in Maryland, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT03610711 about?
NCT03610711 is a clinical study titled "REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer". This is a Phase 1B study assessing the safety of immune checkpoint inhibition after SBRT in patients with recurrent or metastatic gastroesophageal cancer (limited metastatic disease).
What is the current status of trial NCT03610711?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2019-03-06. Estimated completion is 2026-12.
What conditions does trial NCT03610711 study?
This clinical trial studies the following conditions: GastroEsophageal Cancer, Immune Checkpoint Inhibition.
What interventions are being tested in trial NCT03610711?
The interventions under investigation include: Nivolumab (DRUG), Relatlimab (DRUG).
Who is sponsoring clinical trial NCT03610711?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03610711 being conducted?
This trial has 3 study locations across Maryland, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for GastroEsophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03610711's enrollment target sits among peer trials
21 21st of 23 higher than 3 of 23 other GastroEsophageal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other GastroEsophageal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
ACTIVE NOT RECRUITING · Phase 1
-
A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
COMPLETED · Phase 1
-
Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer
COMPLETED · Phase 1
-
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
COMPLETED · Phase 1
-
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI